Apellis Pharmaceuticals (APLS) call put ratio 1.2 calls to 1 put after Biogen (BIIB) acquires
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
William Blair Downgrades Apellis Pharmaceuticals (APLS) to Market Perform
March 31, 2026 11:55 AM EDTWilliam Blair analyst Lachlan Hanbury-Brown downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Apellis Pharmaceuticals click here. For more ratings news on Apellis Pharmaceuticals click here.
Shares of Apellis Pharmaceuticals closed at $17.09 yesterday.
... More